Cambridge Investment Research Advisors’s BioNexus Gene Lab BGLC Stock Holding History

Cambridge Investment Research Advisors’s Portfolio BGLC Stock Details BGLC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,296	Closed	-$6K	–	3477
2024 Q3	$6K	Buy	+1,296	New	+$5.83K	﹤0.01%	3397

Other funds holding BGLC

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SRL

Scientech Research LLC Jersey City, New Jersey $120M AUM 73.62% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cambridge Investment Research Advisors's BGLC Position: Q4 2024 in Review

Cambridge Investment Research Advisors sold out of BioNexus Gene Lab (BGLC) in Q4 2024, closing a stake of 1,296 shares — an estimated $6K sold.

Cambridge Investment Research Advisors first reported a position in BGLC in Q3 2024 and held it in 1 quarter. The position peaked at $6K in Q3 2024. 6 funds tracked by Wall St. Rank hold BGLC as of Q4 2024.

Cambridge Investment Research Advisors reported no remaining BioNexus Gene Lab position as of Q4 2024 after selling out during the quarter.
Cambridge Investment Research Advisors sold 1,296 BioNexus Gene Lab shares in Q4 2024, an estimated $6K.
Cambridge Investment Research Advisors first reported a position in BioNexus Gene Lab in Q3 2024 and held it in 1 quarter.
Cambridge Investment Research Advisors's BioNexus Gene Lab position peaked at $6K in Q3 2024.
6 funds tracked by Wall St. Rank held BioNexus Gene Lab as of Q4 2024.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.